Pharmacokinetics and dialytic clearance of ceftazidime-avibactam in a critically ill patient on continuous venovenous hemofiltration

Antimicrobial Agents and Chemotherapy

Volumn 61, Issue 7, 2017, Pages

  Wenzler, Eric ^a   Bunnell, Kristen L ^a   Bleasdale, Susan C ^b   Benken, Scott ^a   Danziger, Larry H ^a,b   Rodvold, Keith A ^a,b  

^a UNIVERSITY OF ILLINOIS AT CHICAGO   (United States)

^b UNIVERSITY OF ILLINOIS   (United States)

Author keywords

Avibactam; Ceftazidime; Dialysis; Hemofiltration; Pharmacokinetics; Renal replacement

Indexed keywords

AMIKACIN; AVIBACTAM; AVIBACTAM PLUS CEFTAZIDIME; AZTREONAM; CEFEPIME; CEFTAZIDIME; CEFTOLOZANE PLUS TAZOBACTAM; CILASTATIN PLUS IMIPENEM; CIPROFLOXACIN; COLISTIN; GENTAMICIN; LEVOFLOXACIN; MEROPENEM; PIPERACILLIN PLUS TAZOBACTAM; TIMENTIN; TOBRAMYCIN; ANTIINFECTIVE AGENT; AVIBACTAM, CEFTAZIDIME DRUG COMBINATION; AZABICYCLO DERIVATIVE;

ADULT; ANTIBIOTIC RESISTANCE; ANTIBIOTIC SENSITIVITY; AREA UNDER THE CURVE; ARTICLE; ASCITES FLUID; BACTEREMIA; CASE REPORT; CLEARANCE AT STEADY-STATE; CLOSTRIDIUM DIFFICILE INFECTION; CONTINUOUS HEMOFILTRATION; CRITICALLY ILL PATIENT; DISK DIFFUSION; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG HALF LIFE; EMPYEMA; EPSILOMETER TEST; FEMALE; FLOW RATE; HEMODIALYSIS PATIENT; HOSPITALIZATION; HUMAN; IDIOPATHIC DISEASE; KIDNEY FAILURE; KIDNEY GRAFT; LIVER FAILURE; MAXIMUM PLASMA CONCENTRATION; MIDDLE AGED; MINIMUM INHIBITORY CONCENTRATION; MINIMUM PLASMA CONCENTRATION; PLASMA CONCENTRATION-TIME CURVE; PRIORITY JOURNAL; PSEUDOMONAS INFECTION; SEPTIC SHOCK; SINGLE DRUG DOSE; TOXIC MEGACOLON; ULTRAFILTRATION; VOLUME OF DISTRIBUTION AT STEADY-STATE; CRITICAL ILLNESS; DRUG EFFECTS; HEMOFILTRATION; MICROBIAL SENSITIVITY TEST; PSEUDOMONAS AERUGINOSA;

ANTI-BACTERIAL AGENTS; AZABICYCLO COMPOUNDS; CEFTAZIDIME; CRITICAL ILLNESS; HEMOFILTRATION; MICROBIAL SENSITIVITY TESTS; PSEUDOMONAS AERUGINOSA;

EID: 85022091860     PISSN: 00664804     EISSN: 10986596     Source Type: Journal    
DOI: 10.1128/AAC.00464-17     Document Type: Article

References (14)

1. Zasowski EJ, Rybak JM, Rybak MJ. 2015. The beta-lactams strike back: ceftazidime-avibactam. Pharmacotherapy 2015:755–770. https://doi.org/10.1002/phar.1622.
2. Anonymous. September 2015. Avycaz (ceftazidime/avibactam) prescribing information. Actavis, Inc. http://pi.actavis.com/data_stream.asp?product_group=1957&p=pi&language=E. Accessed 14 September 2015.
3. Anonymous. 5 December 2014. Food and Drug Administration Anti-Infective Drugs Advisory Committee Meeting. Ceftazidime-avibactam for injection for treatment of complicated intra-abdominal infection (used in combination with metronidazole), complicated urinary tract infection including acute pyelonephritis, and limited use indication: aerobic Gram-negative infections with limited treatment options. http://www.fda.gov/downloads/AdvisoryCommittees/CommitteesMeetingMaterials/Drugs/Anti-InfectiveDrugsAdvisoryCommittee/UCM425459.pdf. Accessed 25 August 2016.
4. Shields RK, Chen L, Cheng S, Chavda KD, Press EG, Snyder A, Pandey R, Doi Y, Kreiswirth BN, Nguyen MH, Clancy CJ. 28 December 2016. Emergence of ceftazidime-avibactam resistance due to plasmid-borne blaKPC-3 mutations during treatment of carbapenem-resistant Klebsiella pneumoniae infections. Antimicrob Agents Chemother https://doi.org/10.1128/aac.02097-16.
5. Xipell M, Bodro M, Marco F, Losno RA, Cardozo C, Soriano A. 2017. Clinical experience with ceftazidime/avibactam in patients with severe infections, including meningitis and lung abscesses, caused by extensively drug-resistant Pseudomonas aeruginosa. Int J Antimicrob Agents 49:266–268. https://doi.org/10.1016/j.ijantimicag.2016.11.005.
6. Temkin E, Torre-Cisneros J, Beovic B, Benito N, Giannella M, Gilarranz R, Jeremiah C, Loeches B, Machuca I, Jimenez-Martin MJ, Martinez JA, Mora-Rillo M, Navas E, Osthoff M, Pozo JC, Ramos Ramos JC, Rodriguez M, Sanchez-Garcia M, Viale P, Wolff M, Carmeli Y. 24 January 2017. Ceftazidime-avibactam as salvage therapy for infections caused by carbapenem-resistant organisms. Antimicrob Agents Chemother https://doi.org/10.1128/AAC.01964-16.
7. Merdjan H, Rangaraju M, Tarral A. 2015. Safety and pharmacokinetics of single and multiple ascending doses of avibactam alone and in combination with ceftazidime in healthy male volunteers: results of two randomized, placebo-controlled studies. Clin Drug Invest 35:307–317. https://doi.org/10.1007/s40261-015-0283-9.
8. Isla A, Gascon AR, Maynar J, Arzuaga A, Sanchez-Izquierdo JA, Pedraz JL. 2007. In vitro AN69 and polysulphone membrane permeability to ceftazidime and in vivo pharmacokinetics during continuous renal replacement therapies. Chemotherapy 53:194–201. https://doi.org/10.1159/000100864.
9. Traunmüller F, Schenk P, Mittermeyer C, Thalhammer-Scherrer R, Ratheiser K, Thalhammer F. 2002. Clearance of ceftazidime during continuous venovenous haemofiltration in critically ill patients. J Antimicrob Chemother 49:129–134. https://doi.org/10.1093/jac/49.1.129.
10. Ambrose PG, Bhavnani SM, Rubino CM, Louie A, Gumbo T, Forrest A, Drusano GL. 2007. Pharmacokinetics-pharmacodynamics of antimicrobial therapy: it’s not just for mice anymore. Clin Infect Dis 44:79–86. https://doi.org/10.1086/510079.
11. Golper TA, Wedel SK, Kaplan AA, Saad AM, Donta ST, Paganini EP. 1985. Drug removal during continuous arteriovenous hemofiltration: theory and clinical observations. Int J Artif Organs 8:307–312.
12. Pea F, Viale P, Pavan F, Furlanut M. 2007. Pharmacokinetic considerations for antimicrobial therapy in patients receiving renal replacement therapy. Clin Pharmacokinet 46:997–1038. https://doi.org/10.2165/00003088-200746120-00003.
13. Coleman K, Levasseur P, Girard AM, Borgonovi M, Miossec C, Merdjan H, Drusano G, Shlaes D, Nichols WW. 2014. Activities of ceftazidime and avibactam against β-lactamase-producing Enterobacteriaceae in a hollow-fiber pharmacodynamic model. Antimicrob Agents Chemother 58:3366–3372. https://doi.org/10.1128/AAC.00080-14.
14. Berkhout J, Melchers MJ, van Mil AC, Seyedmousavi S, Lagarde CM, Schuck VJ, Nichols WW, Mouton JW. 2016. Pharmacodynamics of ceftazidime and avibactam in neutropenic mice with thigh or lung infection. Antimicrob Agents Chemother 60:368–375. https://doi.org/10.1128/AAC.01269-15.